Gilmore Neil O'Neill
CEO at Editas Medicine Inc.
Sits on 1 board. Last updated September 28, 2026
Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Editas Medicine Inc., 3 years.
Editas Medicine Inc.
Director · CEO
Chief executive roles
Editas Medicine Inc.
· CEO
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 4, 2025 | Editas Medicine Inc. | Open-market sale | −16,632 | $1.71 | $28,441 |
| Dec 3, 2024 | Editas Medicine Inc. | Open-market sale | −1,618 | $2.08 | $3,365 |
| Sep 4, 2024 | Editas Medicine Inc. | Open-market sale | −1,555 | $3.42 | $5,318 |
| Jun 4, 2024 | Editas Medicine Inc. | Open-market sale | −12,191 | $5.50 | $67,051 |
| Mar 5, 2024 | Editas Medicine Inc. | Open-market sale | −77,824 | $9.42 | $733,102 |
| Mar 2, 2024 | Editas Medicine Inc. | Grant or award | +130,700 | — | — |
| Mar 2, 2024 | Editas Medicine Inc. | Grant or award | +72,213 | — | — |
| Mar 2, 2024 | Editas Medicine Inc. | Grant or award | +72,212 | — | — |
| Jun 5, 2023 | Editas Medicine Inc. | Open-market sale | −6,486 | $9.50 | $61,617 |
| Mar 2, 2023 | Editas Medicine Inc. | Grant or award | +50,000 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.